Harnessing genetically engineered cell membrane-derived vesicles as biotherapeutics
Extracellular Vesicles and Circulating Nucleic Acids · 30.01.2024 · 5 (1) · 44-63
DOI: 10.20517/evcna.2023.58 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Extracellular Vesicles and Circulating Nucleic Acids, online erschienen am 30.01.2024. Verfasst von Xiaohong Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Sun Yat-Sen University, Shenzhen 518107, Guangdong, China. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Cell membrane-derived vesicles (CMVs) are particles generated from living cells, including extracellular vesicles (EVs) and artificial extracellular vesicles (aEVs) prepared from cell membranes. CMVs possess considerable potential in drug delivery, regenerative medicine, immunomodulation, disease diagnosis, etc . owing to their stable lipid bilayer structure, favorable biocompatibility, and low toxicity. Although the majority of CMVs inherit certain attributes from the original cells, it is still difficult to execute distinct therapeutic functions, such as organ targeting, signal regulation, and exogenous biotherapeutic supplementation. Hence, engineering CMVs by genetic engineering, chemical modification, and hybridization is a promising way to endow CMVs with specific functions and open up novel vistas for applications. In particular, there is a growing interest in genetically engineered CMVs harnessed to exhibit biotherapeutics. Herein, we outline the preparation strategies and their characteristics for purifying CMVs. Additionally, we review the advances of genetically engineered CMVs utilized to target organs, regulate signal transduction, and deliver biomacromolecules and chemical drugs. Furthermore, we also summarize the emerging therapeutic applications of genetically engineered CMVs in addressing tumors, diabetes, systemic lupus erythematosus, and cardiovascular diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Sun Yat-Sen University, Shenzhen 518107, Guangdong, China.
- Department of Pharmacology, Molecular Cancer Research Center, School of Medicine, Sun Yat-sen University, Shenzhen 518107, Guangdong, China.
Zitieren
APA
Li, X., Wei, Y., Zhang, Z., & Zhang, X. (2024). Harnessing genetically engineered cell membrane-derived vesicles as biotherapeutics. Extracellular Vesicles and Circulating Nucleic Acids, 5(1), 44-63. https://doi.org/10.20517/evcna.2023.58
Vancouver
Li X, Wei Y, Zhang Z, Zhang X. Harnessing genetically engineered cell membrane-derived vesicles as biotherapeutics. Extracellular Vesicles and Circulating Nucleic Acids. 2024;5(1):44-63. doi:10.20517/evcna.2023.58
BibTeX
@article{Li2024,
author = {Li, Xiaohong and Wei, Yuting and Zhang, Zhirang and Zhang, Xudong},
title = {Harnessing genetically engineered cell membrane-derived vesicles as biotherapeutics},
journal = {Extracellular Vesicles and Circulating Nucleic Acids},
year = {2024},
volume = {5},
number = {1},
pages = {44--63},
doi = {10.20517/evcna.2023.58}
}
EUVIMED